A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma

A DNA repair deficiency (DRD) phenotype exists within a subset of metastatic urothelial carcinomas (mUC) predicting benefit from platinum-based chemotherapy. We tested switch maintenance therapy with the poly ADP-ribose polymerase inhibitor rucaparib, following chemotherapy, for DRD biomarker–positi...

Descripción completa

Detalles Bibliográficos
Autores principales: Crabb, Simon J., Hussain, Syed, Soulis, Eileen, Hinsley, Samantha, Dempsey, Laura, Trevethan, Avril, Song, YeePei, Barber, Jim, Frew, John, Gale, Joanna, Faust, Guy, Brock, Susannah, McGovern, Ursula, Parikh, Omi, Enting, Deborah, Sundar, Santhanam, Ratnayake, Gihan, Lees, Kathryn, Birtle, Alison J., Powles, Thomas, Jones, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788980/
https://www.ncbi.nlm.nih.gov/pubmed/35960902
http://dx.doi.org/10.1200/JCO.22.00405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788980/
https://www.ncbi.nlm.nih.gov/pubmed/35960902
http://dx.doi.org/10.1200/JCO.22.00405

Ejemplares similares